Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O00139
UPID:
KIF2A_HUMAN
Alternative names:
Kinesin-2
Alternative UPACC:
O00139; A5YM42; A5YM54; B4DY54; D3DW97; E9PB70; Q7Z5I3; Q8N5Q7
Background:
Kinesin-like protein KIF2A, also known as Kinesin-2, plays a pivotal role in brain development. It is a microtubule-dependent motor that influences microtubule dynamics during axonal growth and is essential for proper mitosis, chromosome alignment, and spindle dynamics.
Therapeutic significance:
KIF2A mutations lead to Cortical dysplasia, complex, with other brain malformations 3, characterized by early-onset epilepsy and cortical development malformations. Understanding KIF2A's role could unveil new therapeutic strategies for these conditions.